Novartis Historical Income Statement
NVS Stock | USD 95.12 0.76 0.81% |
Historical analysis of Novartis income statement accounts such as Selling And Marketing Expenses of 12.8 B can show how well Novartis AG ADR performed in making a profits. Evaluating Novartis income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Novartis's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Novartis AG ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Novartis AG ADR is a good buy for the upcoming year.
Novartis |
About Novartis Income Statement Analysis
Novartis AG ADR Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Novartis shareholders. The income statement also shows Novartis investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Novartis Income Statement Chart
Novartis AG ADR Income Statement is one of the three primary financial statements used for reporting Novartis's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Novartis AG ADR revenue and expense. Novartis Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Novartis' Net Income From Continuing Ops is comparatively stable compared to the past year. Tax Provision is likely to gain to about 1.7 B in 2024, whereas Interest Expense is likely to drop slightly above 550.6 M in 2024. Add Fundamental
Total Revenue
Total revenue comprises all receipts Novartis AG ADR generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Novartis AG ADR minus its cost of goods sold. It is profit before Novartis operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most accounts from Novartis' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Novartis AG ADR current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. At this time, Novartis' Net Income From Continuing Ops is comparatively stable compared to the past year. Tax Provision is likely to gain to about 1.7 B in 2024, whereas Interest Expense is likely to drop slightly above 550.6 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 37.0B | 36.3B | 34.2B | 32.3B | Total Revenue | 52.9B | 51.8B | 46.7B | 46.2B |
Novartis income statement Correlations
Click cells to compare fundamentals
Novartis Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novartis income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 6.5B | 7.1B | 6.1B | 7.2B | 8.3B | 4.3B | |
Interest Expense | 850M | 869M | 811M | 837M | 855M | 550.6M | |
Selling General Administrative | 14.4B | 14.2B | 14.8B | 14.3B | 14.3B | 15.0B | |
Total Revenue | 48.7B | 49.9B | 52.9B | 51.8B | 46.7B | 46.2B | |
Gross Profit | 34.3B | 34.8B | 37.0B | 36.3B | 34.2B | 32.3B | |
Other Operating Expenses | 39.6B | 39.7B | 41.2B | 42.6B | 36.9B | 36.9B | |
Operating Income | 9.1B | 10.2B | 26.9B | 9.2B | 9.8B | 9.9B | |
Ebit | 9.1B | 10.2B | 26.9B | 9.2B | 10.2B | 10.5B | |
Research Development | 9.4B | 9.0B | 9.5B | 10.0B | 11.4B | 7.8B | |
Ebitda | 15.6B | 17.2B | 33.1B | 16.4B | 18.5B | 14.8B | |
Cost Of Revenue | 14.4B | 15.1B | 15.9B | 15.5B | 12.5B | 13.9B | |
Total Operating Expenses | 25.2B | 24.6B | 25.3B | 27.1B | 24.4B | 23.0B | |
Income Before Tax | 8.9B | 9.9B | 26.1B | 8.4B | 9.1B | 10.2B | |
Total Other Income Expense Net | (146M) | (274M) | (811M) | (826M) | (227M) | (215.7M) | |
Net Income | 7.1B | 8.1B | 24.0B | 7.0B | 14.9B | 9.7B | |
Income Tax Expense | 1.8B | 1.8B | 2.1B | 1.4B | 551M | 523.5M | |
Net Income Applicable To Common Shares | 11.7B | 8.1B | 24.0B | 7.0B | 8.0B | 9.8B | |
Minority Interest | 77M | 68M | 3M | 2M | (4M) | (3.8M) | |
Net Income From Continuing Ops | 7.1B | 8.1B | 24.0B | 7.0B | 8.2B | 10.8B | |
Tax Provision | 1.8B | 1.8B | 2.1B | 1.4B | 1.4B | 1.7B | |
Interest Income | 36M | 91M | 14.6B | 379M | 627M | 595.7M | |
Net Interest Income | (645M) | (947M) | (891M) | (633M) | (492M) | (516.6M) | |
Reconciled Depreciation | 5.8B | 6.5B | 6.1B | 7.2B | 9.0B | 7.5B |
Novartis Investors Sentiment
The influence of Novartis' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novartis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Novartis' public news can be used to forecast risks associated with an investment in Novartis. The trend in average sentiment can be used to explain how an investor holding Novartis can time the market purely based on public headlines and social activities around Novartis AG ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Novartis' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novartis' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novartis' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Novartis.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novartis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novartis' short interest history, or implied volatility extrapolated from Novartis options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Novartis Stock analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 4.987 | Dividend Share 3.919 | Earnings Share 4.1 | Revenue Per Share 22.467 | Quarterly Revenue Growth 0.074 |
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.